Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) have been given a consensus recommendation of “Moderate Buy” by the four analysts that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among brokers that have covered the stock in the last year is $14.00.

Several research firms recently commented on RADX. Weiss Ratings reiterated a “sell (e+)” rating on shares of Radiopharm Theranostics in a research note on Thursday, January 22nd. Wall Street Zen lowered Radiopharm Theranostics to a “strong sell” rating in a research note on Friday, January 23rd.

Institutional Investors Weigh In On Radiopharm Theranostics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in RADX. Hsbc Holdings PLC purchased a new stake in Radiopharm Theranostics during the fourth quarter valued at about $1,007,000. Virtu Financial LLC purchased a new position in shares of Radiopharm Theranostics in the fourth quarter worth about $76,000. Jane Street Group LLC bought a new stake in shares of Radiopharm Theranostics in the fourth quarter valued at approximately $76,000. Marex Group plc purchased a new stake in shares of Radiopharm Theranostics during the 4th quarter valued at approximately $54,000. Finally, PNC Financial Services Group Inc. lifted its stake in shares of Radiopharm Theranostics by 100.0% during the 3rd quarter. PNC Financial Services Group Inc. now owns 16,000 shares of the company’s stock valued at $88,000 after buying an additional 8,000 shares in the last quarter.

Radiopharm Theranostics Stock Up 1.1%

Shares of RADX stock opened at $4.65 on Thursday. Radiopharm Theranostics has a 52 week low of $3.62 and a 52 week high of $16.25. The firm’s 50-day simple moving average is $4.74 and its two-hundred day simple moving average is $5.11.

Radiopharm Theranostics (NASDAQ:RADX) last released its earnings results on Wednesday, January 28th. The company reported ($1.58) earnings per share for the quarter. The business had revenue of $0.46 million for the quarter.

About Radiopharm Theranostics

Radiopharm Theranostics, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of radiopharmaceutical products for both diagnostic imaging and targeted radiotherapeutic applications. By harnessing the unique properties of radioisotopes, the company aims to improve the precision of disease detection and deliver therapeutic payloads directly to diseased tissues, particularly in oncology.

The company’s research and development efforts are concentrated on a pipeline of radioligand therapies and companion diagnostic agents designed to address a variety of tumor types.